Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXT9RP
|
||||
| Drug Name |
4-(2-(benzo[d][1,3]dioxol-5-yl)ethylamino)-1-methyl-N-(4-(trifluoromethyl)phenyl)-1H-imidazole-5-carboxamide
|
||||
| Synonyms |
CHEMBL241466
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C21H19F3N4O3
|
||||
| Canonical SMILES |
Cn1cnc(NCCc2ccc3OCOc3c2)c1C(=O)Nc4ccc(cc4)C(F)(F)F
|
||||
| InChI |
InChI=1S/C21H19F3N4O3/c1-28-11-26-19(25-9-8-13-2-7-16-17(10-13)31-12-30-16)18(28)20(29)27-15-5-3-14(4-6-15)21(22,23)24/h2-7,10-11,25H,8-9,12H2,1H3,(H,27,29)
|
||||
| InChIKey |
BPKFWXHEWJBXSS-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.